natgillin/translations-raw huggingface dataset:
Lactation Ciprofloxacin is excreted in breast milk.
83 Dojenje Ciprofloksacin se izloča v materino mleko.
83 4.7 Effects on ability to drive and use machines
4. 7 Vpliv na sposobnost vožnje in upravljanja s stroji
Blood and Lymphatic System Disorders
limfatičnega
Eosinophilia
nevtropenija
Leukopenia Anaemia Neutropenia Leukocytosis Thrombocytopenia Thrombocytaemia
sistema
Haemolytic anaemia Agranulocytosis Pancytopenia (life- threatening) Bone marrow depression (life- threatening)
levkocitoza
Immune System Disorders
pancitopenija
Allergic reaction Allergic oedema / angiooedema
trombocitopenija trombocitemija
Anaphylactic reaction Anaphylactic shock (life- threatening) (see section 4.4) Serum sickness- like reaction
(smrtno nevarna) depresija kostnega mozga (smrtno nevarna)
Metabolism and Nutrition Disorders
anafilaktična
Anorexia
reakcija
Hyperglycaemia
alergijski
Psychiatric Disorders
anafilaktični
Psychomotor hyperactivity / agitation
edem/ angioedem
Confusion and disorientation Anxiety reaction Abnormal dreams Depression Hallucinations
šok (smrtno nevaren) (glejte poglavje 4. 4) reakcija, podobna serumski bolezni
Psychotic reactions (see section 4.4)
Presnovne in prehranske motnje
84 System Organ
84
Liver necrosis (very rarely progressing to life-threatening hepatic failure) (see section 4.4)
smrtno
Musculoskeletal pain (e. g. extremity pain, back pain, chest pain) Arthralgia
(predvsem
Myalgia Arthritis Increased muscle tone and cramping
hrbtu, prsnem košu) artralgija
Prothrombin level abnormal Increased amylase
vrednosti protrombina zvišanje vrednosti
86 An overdose of 12 g has been reported to lead to mild symptoms of toxicity.
Prekomerni odmerek 12 g je povzročil blage simptome toksičnosti.
Efficacy mainly depends on the relation between the maximum concentration in serum (Cmax) and the minimum inhibitory concentration (MIC) of ciprofloxacin for a bacterial pathogen and the relation between the area under the curve (AUC) and the MIC.
Učinek je odvisen predvsem od razmerja med Najvišjo serumsko koncentracijo (Cmax) in minimalno inhibitorno koncentracijo (MIK) ciprofloksacina proti bakterijam oziroma razmerja med področjem pod krivuljo (AUC) in MIK.
Neisseria gonorrhoeae Neisseria meningitidis Non-species-related breakpoints*
Haemophilus influenzae in Moraxella catarrhalis Neisseria gonorrhoeae Neisseria meningitidis Mejne vrednosti za nespecifične vrste *
S ≤ 0.03 mg/ L S ≤ 0.03 mg/ L S ≤ 0.5 mg/ L
S < 0, 5 mg/ l S < 0, 03 mg/ l S < 0, 03 mg/ l S < 0, 5 mg/ l
> 0.06 mg/ L > 0.06 mg/ L R > 1 mg/ L
R > 0, 5 mg/ l R > 0, 06 mg/ l R > 0, 06 mg/ l R > 1 mg/ l
1 Staphylococcus spp. - breakpoints for ciprofloxacin relate to high dose therapy. * Non-species-related breakpoints have been determined mainly on the basis of PK/ PD data and are independent of MIC distributions of specific species.
88 1 Staphylococcus spp. – mejne vrednosti za ciprofloksacin povezane z zdravljenjem z visokimi odmerki. * Mejne vrednosti za nespecifične vrste so določili na podlagi farmakokinetičnih in farmakodinamičnih podatkov in so neodvisne od distribucije MIK- a za specifične vrste.
88 COMMONLY SUSCEPTIBLE SPECIES Aerobic Gram-positive micro-organisms Bacillus anthracis (1) Aerobic Gram-negative micro-organisms Aeromonas spp.
SPLOŠNO OBČULJIVE VRSTE aerobni, po Gramu pozitivni mikroorganizmi Bacillus anthracis( 1) aerobni, po Gramu negativni mikroorganizmi Aeromonas spp.
Yersinia pestis Anaerobic micro-organisms Mobiluncus Other micro-organisms Chlamydia trachomatis ($) Chlamydia pneumoniae ($) Mycoplasma hominis ($) Mycoplasma pneumoniae ($) SPECIES FOR WHICH ACQUIRED RESISTANCE MAY BE A PROBLEM Aerobic Gram-positive micro-organisms Enterococcus faecalis ($) Staphylococcus spp. *(2) Aerobic Gram-negative micro-organisms Acinetobacter baumannii+ Burkholderia cepacia+* Campylobacter spp. +* Citrobacter freundii* Enterobacter aerogenes Enterobacter cloacae* Escherichia coli* Klebsiella oxytoca Klebsiella pneumoniae* Morganella morganii* Neisseria gonorrhoeae* Proteus mirabilis* Proteus vulgaris* Providencia spp.
(2)
Natural intermediate susceptibility in the absence of acquired mechanism of resistance (1):
Propionibacterium acnes ODPORNI ORGANIZMI aerobni, po Gramu pozitivni mikroorganizmi Actinomyces Enteroccus faecium Listeria monocytogenes aerobni, po Gramu negativni mikroorganizmi Stenotrophomonas maltophilia anaerobni mikroorganizmi razen mikroorganizmov navedenih zgoraj drugi mikroorganizmi Mycoplasma genitalium Ureaplasma urealitycum * klinično učinkovitost so dokazali pri občutljivih izolatih za odobrene klinične indikacije + stopnja odpornosti ≥ 50% v eni ali več državah Evropske unije ($) naravna vmesna občutljivost v odsotnosti pridobljene odpornosti (1):
Single doses of 100-750 mg produced dose-dependent maximum serum concentrations (Cmax) between 0.56 and 3.7 mg/ L.
90 Po enkratnih odmerkih od 100 do 750 mg so Najvišje serumske koncentracije med 0, 56 in 3, 7 mg/ l.
90 Ciprofloxacin is largely excreted unchanged both renally and, to a smaller extent, faecally.
Ciprofloksacin se izloča večinoma nespremenjen skozi ledvice, preostanek pa z blatom.
91 6.2 Incompatibilities
6. 2 Inkompatibilnosti
Ciprofloxacin Bayer and associated names (see Annex I) 250 mg oral suspension in single-dose sachets [See Annex I - To be completed nationally]
Ciprofloksacin Bayer in povezana imena (Glejte Dodatek I) 250 mg peroralna suspenzija, vrečice za enkratno uporabo [Glejte Dodatek I – Izpolni država članica]
Oral suspension (in single-dose sachets) [To be completed nationally]
peroralna suspenzija (vrečice za enkratno uporabo) [Izpolni država članica]
The Ciprofloxacin Bayer 250 mg oral suspension in single-dose sachets are indicated for the treatment of the following infections (see sections 4.4 and 5.1).
Zdravilo Ciprofloksacin Bayer 250 mg peroralna suspenzija, vrečice za enkratno uporabo se uporablja za zdravljenje naslednjih okužb (glejte poglavji 4. 4 in 5. 1)..
• Pelvic inflammatory disease including cases due to Neisseria gonorrhoeae In the above genital tract infections when thought or known to be due to Neisseria gonorrhoeae it is particularly important to obtain local information on the prevalence of resistance to ciprofloxacin and to confirm susceptibility based on laboratory testing.
Občutljivost mora biti laboratorijsko potrjena.
• Infections of the gastro-intestinal tract (e. g. travellers’ diarrhoea)
• okužbe prebavil (npr. potovalna driska)
• Infections of the skin and soft tissue caused by Gram-negative bacteria
94 • okužbe kože in mehkih tkiv, ki jih povzročajo po Gramu negativne bakterije
93 • Malignant external otitis
• maligno vnetje zunanjega ušesa
• Treatment of infections in neutropenic patients
• zdravljenje okužb pri bolnikih z nevtropenijo
• Broncho-pulmonary infections in cystic fibrosis caused by Pseudomonas aeruginosa • Complicated urinary tract infections and pyelonephritis • Inhalation anthrax (post-exposure prophylaxis and curative treatment)
− akutno pljučno poslabšanje cistične fibroze, ki ga povzroča Pseudomonas aeruginosa − zapletene okužbe sečil in pielonefritis − inhalacijski vranični prisad (preprečevanje in zdravljenje po izpostavitvi povzročitelju)
Daily dose in mg
dnevni odmerki
500 mg twice daily to 750 mg twice daily
500 mg do 750 mg dvakrat na dan 95
2-4 weeks (acute) to 4-6 weeks (chronic)
2 do 4 tednov (akutni) do 4 do 6 tednov (kronični)
500 mg as a single dose
500 mg enkrat na dan 96
10 mg/ kg body weight twice daily to 15 mg/ kg
10 mg/ kg
60 days from the
60 dni po potrjeni izpostavitvi Bacillus anthracis
Renal and hepatic impairment
97 Okvarjeno delovanje ledvic in jeter
124
124 do 168 > 169
250-500 mg every 24 h
250 – 500 mg/ 24 h
Ciprofloxacin should not be taken with dairy products (e. g. milk, yoghurt) or mineral-fortified fruit juice (e. g. calcium-fortified orange juice) (see section 4.5).
Ciprofloksacin se ne sme jemati hkrati z mlečnimi izdelki (npr. mleko, jogurt) ali pijačami, obogatenimi z minerali (npr. s kalcijem obogaten pomarančni sok) (glejte poglavje 4. 5).
In severe cases or if the patient is unable to take oral suspension (e. g. patients on enteral nutrition), it is recommended to commence therapy with intravenous ciprofloxacin until a switch to oral administration is possible.
V hudih primerih ali če bolnik ne more jemati peroralne suspenzije (npr. bolniki na enteralni prehrani), je priporočena uporaba intravenskih oblik ciprofloksacina, dokler ni možna uporaba peroralnih oblik ciprofloksacina.
In such infections ciprofloxacin must be co-administered with other appropriate antibacterial agents.
V teh primerih je treba sočasno s ciprofloksacinom uporabiti tudi druga ustrezna antibakterijska zdravila.
Intra-abdominal infections There are limited data on the efficacy of ciprofloxacin in the treatment of post-surgical intra-abdominal infections.
98 Intraabdominalne okužbe Podatki o učinkovitosti ciprofloksacina pri zdravljenju intraabdominalnih okužb po kirurških posegih so omejeni.
97 The choice of ciprofloxacin should take into account information on resistance to ciprofloxacin in relevant pathogens in the countries visited.
Potovalna driska Pri zdravljenju bolnikov s potovalno drisko je potrebno upoštevati podatke o odpornosti povzročiteljev na ciprofloksacin v državah, v katere so potovali.
Treating physicians should refer to national and / or international consensus documents regarding the treatment of anthrax.
Lečeči zdravnik mora upoštevati nacionalne/ mednarodne smernice glede zdravljenja vraničnega prisada.
Musculoskeletal System Ciprofloxacin should generally not be used in patients with a history of tendon disease/ disorder related to quinolone treatment.
99 Mišičnoskeletni sistem Ciprofloksacin se praviloma ne sme uporabljati pri bolnikih z boleznimi/ poškodbami kit v anamnezi, ki so bile povezane z zdravljenjem s kinoloni.
98 Tendinitis and tendon rupture (especially Achilles tendon), sometimes bilateral, may occur with ciprofloxacin, as soon as the first 48 hours of treatment.
Včasih se lahko po zdravljenju s ciprofloksacinom (v prvih 48 urah zdravljenja) pojavi tendinitis ali ruptura kite (predvsem Ahilove tetive), včasih obojestransko.
Ciprofloxacin should be avoided in these patients unless the potential benefit is considered to outweigh the possible risk.
100 ciprofloksacinom, razen če je korist zdravljenja večja od tveganja.
99 Cytochrome P450 Ciprofloxacin inhibits CYP1A2 and thus may cause increased serum concentration of concomitantly administered substances metabolised by this enzyme (e. g. theophylline, clozapine, ropinirole, tizanidine).
Citokrom P450 Ciprofloksacin zavira encimski sistem CYP1A2, kar lahko povzroči zvišanje serumskih koncentracij sočasno danih zdravil, ki se presnavljajo s pomočjo tega encima (npr. teofilin, klozapin, ropinirol, tizanidin).
10-fold, range:
101 10- kratno, razpon:
100 Theophylline
Teofilin
Oral ant-icoagulants
Peroralni antikoagulanti
There have been many reports of increases in oral anti-coagulant activity in patients receiving antibacterial agents, including fluoroquinolones.
V večih primerih so poročali o zvečanem antikoagulacijskem učinku pri bolnikih, ki so dobivali antibakterijska zdravila, predvsem fluorokinolone.
It is recommended that the INR should be monitored frequently during and shortly after co-administration of ciprofloxacin with an oral anti-coagulant agent.
Med zdravljenjem in kmalu po sočasni uporabi ciprofloksacina in peroralnega antikoagulanta je treba pogosteje določati vrednosti INR.
In juvenile and prenatal animals exposed to quinolones, effects on immature cartilage have been observed, thus, it cannot be excluded that the drug could cause damage to articular cartilage in the human immature organism / foetus (see section 5.3).
Pri mladih in prenatalnih živalih, ki so bile izpostavljene 102 kinolonom, so opažali učinke na nerazvitem hrustancu, zato se možnosti poškodb sklepnega hrustanca pri nerazvitih organizmih/ fetusih ne da zanesljivo izključiti (glejte poglavje 5. 3).
101 4.7 Effects on ability to drive and use machines
4. 7 Vpliv na sposobnost vožnje in upravljanja s stroji
Hyperglycaemia
reakcija
Psychiatric Disorders
alergijski
Psychomotor hyperactivity / agitation
anafilaktični
Confusion and disorientation Anxiety reaction Abnormal dreams Depression Hallucinations
edem/ angioedem
Psychotic reactions (see section 4.4)
šok (smrtno nevaren) (glejte poglavje 4. 4) reakcija, podobna serumski
102 System Organ
Organski
Nervous System Disorders
Presnovne in prehranske motnje
Headache Dizziness Sleep disorders Taste disorders
hiperglikemija
Par- and Dysaesthesia Hypoaesthesia Tremor Seizures (see section 4.4) Vertigo
motnje
Migraine Disturbed coordination Gait disturbance Olfactory nerve disorders Intracranial hypertension
na
Peripheral neuropathy (see section 4.4)
dezorientiranost
Eye Disorders Ear and Labyrinth Disorders
hiperaktivnos t / agitacija
Visual disturbances Tinnitus Hearing loss / Hearing impaired
anksiozna reakcija nočne more depresija halucinacije
Visual colour distortions
(glejte poglavje 4. 4)
Cardiac Disorders
parestezija in
Tachycardia
migrena
Ventricular arrhythmia, QT prolongation, torsades de pointes *
periferna
Vascular Disorders
živčevja
Vasodilatation Hypotension Syncope
disestezija
Vasculitis
nevropatija
Respiratory, Thoracic and Mediastinal Disorders
motnje spanja motnje okusa
Dyspnoea (including asthmatic condition)
hipoestezija tremor krči (glejte poglavje 4. 4) vrtoglavica
Gastrointestinal Disorders
koordinacije motnje ravnotežja motnje vohanja zvišan intrakranialni tlak
Nausea Diarrhoea
(glejte poglavje 4. 4)
Vomiting Gastrointestinal and abdominal pains Dyspepsia Flatulence
Očesne bolezni Ušesne bolezni, vključno z motnjami labirinta
Pancreatitis
Srčne bolezni
Hepatobiliary Disorders
tahikardija
Increase in transaminases Increased bilirubin
ventrikularne aritmije, podaljšanje intervala QT, torsade de pointes *
Hepatic impairment Cholestatic icterus Hepatitis
Žilne bolezni Bolezni dihal, prsnega koša in mediastinal nega prostora
Liver necrosis (very rarely progressing to life-threatening hepatic failure) (see section 4.4)
vazodilatacija hipotenzija sinkopa dispneja (tudi astmatsko stanje)
Skin and Subcutaneous Tissue Disorders
vaskulitis
Rash Pruritus Urticaria
pankreatitis
Photosensitivity reactions (see section 4.4)
bolečine v trebuhu dispepsija
Petechiae Erythema multiforme Erythema nodosum Stevens- Johnson syndrome (potentially life- threatening)
104
103 System Organ
Organski
1/ 100
< 1/ 100 flatulenca
Toxic epidermal necrolysis (potentially life- threatening)
razpoložljivih podatkov)
(cannot be estimated from available data)
nevarno jetrno odpoved)
Musculoskeletal, Musculoskeletal
reakcije (glejte
Myalgia
Bolezni
Muscular
artritis
Connective Tissue and Bone Disorders
mišičnega tonusa
pain (e. g. extremity pain, back pain, chest pain) Arthralgia
okončinah,
Arthritis Increased muscle tone and cramping
hrbtu, prsnem košu) artralgija
weakness Tendinitis Tendon rupture (predominantly Achilles tendon) (see section 4.4) Exacerbation of symptoms of myasthenia gravis (see section 4.4)
Ahilove tetive) (glejte poglavje 4. 4) poslabšanje miastenije gravis (glejte poglavje 4. 4)
Asthenia Fever
≥ 1/ 10. 000 do <
Oedema Sweating (hyperhidrosis)
razpoložljivih podatkov)
The degree of cross-resistance between ciprofloxacin and other fluoroquinolones that results is variable.
Posamezne mutacije ne povzročajo
Single mutations may not result in clinical resistance, but multiple mutations generally result in clinical resistance to many or all active substances within the class.
106 klinične odpornosti, večkratne mutacije pa pogosto povzročijo klinično odpornost na večino ali vse zdravilne učinkovine v skupini.
Plasmid- mediated resistance encoded by qnr-genes has been reported.
Poročali so tudi o odpornosti, pridobljeni s plazmidi, ki imajo qnr gene.
Enterobacteria Pseudomonas Acinetobacter Staphylococcus spp.1
Enterobacteria Pseudomonas Acinetobacter Staphylococcus spp. 1 Haemophilus influenzae in Moraxella catarrhalis Neisseria gonorrhoeae Neisseria meningitidis *
R > 1 mg/ L R > 1 mg/ L R > 1 mg/ L R > 1 mg/ L
R > 1 mg/ l R > 1 mg/ l R > 1 mg/ l R > 1 mg/ l R > 0, 5 mg/ l R > 0, 06 mg/ l R > 0, 06 mg/ l
Haemophilus influenzae and Moraxella catarrhalis
Mejne vrednosti za nespecifične vrste
S ≤ 0.5 mg/ L
S < 0, 5 mg/ l
They are for use only for species that have not been given a species-specific breakpoint and not for those species
Uporabljajo se samo za vrste, pri katerih mejne vrednosti niso bile določene in se ne uporabljajo za vrste, pri katerih se test občutljivosti ne priporoča.
105 where susceptibility testing is not recommended.
Razširjenost pridobljene odpornosti se lahko za izbrane vrste razlikuje geografsko in časovno.
106 COMMONLY SUSCEPTIBLE SPECIES Aerobic Gram-positive micro-organisms Bacillus anthracis (1) Aerobic Gram-negative micro-organisms Aeromonas spp.
107 SPLOŠNO OBČULJIVE VRSTE aerobni, po Gramu pozitivni mikroorganizmi Bacillus anthracis( 1) aerobni, po Gramu negativni mikroorganizmi Aeromonas spp.
Moraxella catarrhalis * Neisseria meningitidis Pasteurella spp.
Moraxella catarrhalis * Neisseria meningitidis Pasturella spp.
Aerobic Gram-negative micro-organisms Acinetobacter baumannii+ Burkholderia cepacia+* Campylobacter spp. +* Citrobacter freundii* Enterobacter aerogenes Enterobacter cloacae * Escherichia coli* Klebsiella oxytoca Klebsiella pneumoniae* Morganella morganii* Neisseria gonorrhoeae* Proteus mirabilis* Proteus vulgaris* Providencia spp.
Yersinia pestis anaerobni mikroorganizmi Mobinculus drugi mikroorganizmi Chlamydia trachomatis ($) Chlamydia pneumoniae ($) Mycoplasma hominis ($) Mycoplasma pneumoniae ($) VRSTE, PRI KATERIH JE PRIDOBLJENA ODPORNOST LAHKO DVOMLJIVA aerobni, po Gramu pozitivni mikroorganizmi Enterococcus faecalis ($) Staphylococcus spp. * (2) aerobni, po Gramu negativni mikroorganizmi Acinetobacter baumannii+ Burkholderia cepacia + * Campylobacter spp. + * Citrobacter freundii * Enterobacter aerogenes Enterobacter cloacae * Escherichia coli * Klebsiella oxytoca Klebsiella pneumoniae * Morganella morganii * Neisseria gonorrhoeae * Proteus mirabilis * Proteus vulgaris * Providencia spp.
Pseudomonas aeruginosa* Pseudomonas fluorescens Serratia marcescens*
Pseudomonas aeruginosa * Pseudomonas fluorescens Serratia marcescens * anaerobni mikroorganizmi Peptostreptococcus spp.
Propionibacterium acnes
Propionibacterium acnes ODPORNI ORGANIZMI aerobni, po Gramu pozitivni mikroorganizmi Actinomyces Enteroccus faecium Listeria monocytogenes
Natural intermediate susceptibility in the absence of acquired mechanism of resistance (1):
108 aerobni, po Gramu negativni mikroorganizmi Stenotrophomonas maltophilia anaerobni mikroorganizmi razen mikroorganizmov navedenih zgoraj drugi mikroorganizmi Mycoplasma genitalium Ureaplasma urealitycum * klinično učinkovitost so dokazali pri občutljivih izolatih za odobrene klinične indikacije + stopnja odpornosti ≥ 50% v eni ali več državah Evropske unije ($) naravna vmesna občutljivost v odsotnosti pridobljene odpornosti (1):
The treating physician should refer to national and / or international consensus documents regarding treatment of anthrax.
Lečeči zdravnik mora upoštevati nacionalne in/ ali mednarodne smernice glede zdravljenja vraničnega prisada.
108 Low concentrations of four metabolites have been reported, which were identified as: desethyleneciprofloxacin (M 1), sulphociprofloxacin (M 2), oxociprofloxacin (M 3) and formylciprofloxacin (M 4).
To so desetilenciprofloksacin (M1), sulfociprofloksacin (M2), oksociprofloksacin (M3) in formilciprofloksacin (M4).
Elimination
109 Izločanje
109 6.
110 6.
Take the prescribed amount of sachets.
Vzeti je treba predpisano število vrečic.
Ciprofloxacin Bayer and associated names (see Annex I) 500 mg oral suspension in single-dose sachets [See Annex I - To be completed nationally]
Ciprofloksacin Bayer in povezana imena (Glejte Dodatek I) 500 mg peroralna suspenzija, vrečice za enkratno uporabo [Glejte Dodatek I – Izpolni država članica]
The Ciprofloxacin Bayer 500 mg oral suspension in single-dose sachets are indicated for the treatment of the following infections (see sections 4.4 and 5.1).
Zdravilo Ciprofloksacin Bayer 500 mg peroralna suspenzija, vrečice za enkratno uporabo se uporablja za zdravljenje naslednjih okužb (glejte poglavji 4. 4 in 5. 1)..
• Infections of the skin and soft tissue caused by Gram-negative bacteria
112 • okužbe kože in mehkih tkiv, ki jih povzročajo po Gramu negativne bakterije
111 • Malignant external otitis
• maligno vnetje zunanjega ušesa
500 mg twice daily to 750 mg twice daily
500 mg do 750 mg dvakrat na dan 113
weeks (acute) to 4 to6 weeks (chronic)
2 do 4 tednov (akutni) do 4 do 6 tednov (kronični)
500 mg as a single dose
500 mg enkrat na dan 114
113 Indications
indikacije
Oral suspension in single-dose sachets can be taken independent of mealtimes.
Peroralna suspenzija se vzame neodvisno od obrokov hrane.
115 Travellers’ diarrhoea The choice of ciprofloxacin should take into account information on resistance to ciprofloxacin in relevant pathogens in the countries visited.
116 Potovalna driska Pri zdravljenju bolnikov s potovalno drisko je potrebno upoštevati podatke o odpornosti povzročiteljev na ciprofloksacin v državah, v katere so potovali.
Nevertheless, in very rare instances, after microbiological documentation of the causative organism and evaluation of the risk/ benefit balance, ciprofloxacin may be prescribed to these patients for the treatment of certain severe infections, particularly in the event of failure of the standard therapy or bacterial resistance, where the microbiological data may justify the use of ciprofloxacin.
V zelo redkih primerih, glede na mikrobiološke izvide o povzročiteljih in oceni tveganja in koristi, se lahko ciprofloksacin predpiše tudi tem bolnikom za zdravljenje posebno hudih okužb, predvsem če je bilo standardno zdravljenje neuspešno ali odpornost 117 bakterije opravičuje uporabo ciprofloksacina.
116 Tendinitis and tendon rupture (especially Achilles tendon), sometimes bilateral, may occur with ciprofloxacin, as soon as the first 48 hours of treatment.
Včasih se lahko po zdravljenju s ciprofloksacinom (v prvih 48 urah zdravljenja) pojavi tendinitis ali ruptura kite (predvsem Ahilove tetive), včasih obojestransko.
117 Cytochrome P450 Ciprofloxacin inhibits CYP1A2 and thus may cause increased serum concentration of concomitantly administered substances metabolised by this enzyme (e. g. theophylline, clozapine, ropinirole, tizanidine).
118 Citokrom P450 Ciprofloksacin zavira encimski sistem CYP1A2, kar lahko povzroči zvišanje serumskih koncentracij sočasno danih zdravil, ki se presnavljajo s pomočjo tega encima (npr. teofilin, klozapin, ropinirol, tizanidin).
118 Theophylline
119 Teofilin
119 4.7 Effects on ability to drive and use machines
120 4. 7 Vpliv na sposobnost vožnje in upravljanja s stroji
Psychiatric Disorders
dezorientiranost
Psychomotor hyperactivity / agitation
hiperaktivnos t / agitacija
Confusion and disorientation Anxiety reaction Abnormal dreams Depression Hallucinations
anksiozna reakcija
120 System Organ
Organski
1/ 1 000
1/ 1. 000 nočne more depresija halucinacije
Nervous System Disorders
parestezija in
Headache Dizziness Sleep disorders Taste disorders
motnje spanja motnje okusa
Hepatic impairment Cholestatic icterus Hepatitis
zvišanje vrednosti bilirubina
Liver necrosis (very rarely progressing to life-threatening hepatic failure) (see section 4.4)
nevarno jetrno odpoved)
121 System Organ
fotosenzitivne
Common
petehije
Uncommon
Organski
Very Rare
Občasni
Frequency
Redki
Skin and Subcutaneous Tissue Disorders
reakcije (glejte
Rash Pruritus Urticaria
koprivnica
Photosensitivity reactions (see section 4.4)
poglavje 4. 4)
Paediatric patients The incidence of arthropathy, mentioned above, is referring to data collected in studies with adults.
123 Pediatrični bolniki Pogostnost pojava zgoraj omenjene artropatije, je podana na podlagi zbranih podatkov iz študij pri odraslih.
122 An overdose of 12 g has been reported to lead to mild symptoms of toxicity.
Prekomerni odmerek 12 g je povzročil blage simptome toksičnosti.
EUCAST Recommendations
124 EUCAST (The European Committee on Antimicrobial Succeptibility Testing) priporočila